Article
Heterozygote Advantage of the Type II Deiodinase Thr92Ala Polymorphism on Intrahospital Mortality of COVID-19.
The Journal of clinical endocrinology and metabolism - 17 May 2022
de Lima Beltrão Fabyan Esberard, de Almeida Beltrão Daniele Carvalhal, Carvalhal Giulia, de Lima Beltrão Fabricia Elizabeth, de Souza Braga Filho Jair, de Brito Oliveira Jocyel, de Jesus Joice Dos Santos, Machado Gabriel Jeferson Rodríguez, Dos Santos Silva Hatilla, Teixeira Helena Mariana Pitangueira, Rodrigues Juliana Lopes, de Figueiredo Camila Alexandrina Viana, Dos Santos Costa Ryan, Hecht Fabio, Bianco Antonio C, da Conceição Rodrigues Gonçalves Maria, Ramos Helton Estrela
Abstract excerpt
CONTEXT: The type 2 deiodinase and its Thr92Ala-DIO2 polymorphism have been linked to clinical outcomes in acute lung injury and pulmonary fibrosis. OBJECTIVE: Our objectives were to evaluate were cumulative mortality during admission according to Thr92Ala-DIO2 polymorphism. METHODS: Here we conducted an observational, longitudinal, and prospective cohort study to investigate a possible association between the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.